NCT05055063 2025-12-18A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple MyelomaM.D. Anderson Cancer CenterPhase 1 Recruiting30 enrolled